
Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
IN VIVO
Start-Up
The RPM Report
Medtech Insight
Sign up
now
|
|
|
2010
Networking Opportunities and Continuing Education
IN3 Europe + Investor Day
April 28-30, 2010 - Paris, France
More information... |
 |
 |
|
|
Wharton/Windhover Program
Pharma Program For Executives
June 7-11, 2010 - Philadelphia, PA
More information... |
 |
|
|
IN3 East +
Investor Day
June 9-11, 2010 - Boston, MA
More information... |
 |
 |
|
|
Euro-Biotech Forum
June 28-30, 2010 - Paris, France
More information... |
 |
 |
|
|
Pharmaceutical Strategic Alliances
September 21-23, 2010 - New York, NY
More information...
- Add to MS Outlook |
 |
|
|
2010 Phoenix Conference
To Be Announced - Scottsdale, AZ
More information... |
 |
|
|
IN3 Summit +
Investor Day
October 27-29, 2010 - San Francisco, CA
More information...
- Add to MS Outlook |
 |
 |
|
|
PharmAsia Summit
To Be Announced - San Francisco, CA
More Information... |
 |
|
|
Therapeutic Area Partnerships
To Be Announced - Boston, MA
More Information... |
 |
 |
|
|
FDA/CMS Summit
December 9-10, 2010 - Washington, DC
More Information...
- Add to MS Outlook |
 |
|
|
Bohemian Medical Device Summit
To Be Announced - Budapest, Hungary
More Information... |
 |
|
|
BIOWindhover/
Pharma Strategic Outlook
To Be Announced - New York, NY
More information... |
 |
 |
|
|
IN3 West
+ Investor Day
To Be Announced - Las Vegas, NV
More information... |
 |
 |
|
|
rEvolution 2011
To Be Announced - Miami, FL
More information... |
 |
|
|
 |
|
|
|
|
| |
 |
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)
The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|